Indoco Remedies Limited (NSE:INDOCO)
India · Delayed Price · Currency is INR | Market Cap | 19.40B -16.2% |
| Revenue (ttm) | 18.45B +10.8% |
| Net Income | -951.50M |
| EPS | -10.70 |
| Shares Out | 92.30M |
| PE Ratio | n/a |
| Forward PE | 26.78 |
| Dividend | 0.20 (0.10%) |
| Ex-Dividend Date | Sep 4, 2025 |
| Volume | 101,419 |
| Open | 210.00 |
| Previous Close | 209.66 |
| Day's Range | 209.09 - 215.50 |
| 52-Week Range | 162.19 - 349.80 |
| Beta | 0.62 |
| Analysts | Hold |
| Price Target | 276.25 (+31.43%) |
| Earnings Date | May 7, 2026 |
About Indoco Remedies
Indoco Remedies Limited manufactures and markets formulations and active pharmaceutical ingredients in India and internationally. It offers products for gastrointestinal, anti-infectives, respiratory, stomatological, vitamins/minerals/nutrients, urological, ophthal/ontological, dermatology, pain/analgesic, cardiac, anti-diabetic, and gynaecological therapeutic areas. The company also provides branded generics comprising analgesic tablets and topical preparations; anti-hypertensive; protein supplements; multivitamin tablets and syrups; antibioti... [Read more]
Financial Performance
In fiscal year 2026, Indoco Remedies's revenue was 18.45 billion, an increase of 10.84% compared to the previous year's 16.65 billion. Losses were -951.50 million, 29.0% more than in 2025.
Financial StatementsNews
Pharma sector stocks today, May 29: Wockhardt jumps 7.40%, Indoco Remedies rises 3.46%, Sudeep Pharma up 3.45%
The pharmaceutical stocks traded mixed on May 29, 2026, during the morning session. While some stocks like Wockhardt, Indoco Remedies, and Sudeep Pharma posted strong gains, a few others saw…
Indoco Remedies receives EU GMP certification for Baddi plant
Indoco Remedies Ltd. has announced that its Oral Solid Dosage (OSD) manufacturing facility at Baddi, Himachal Pradesh, has received EU GMP certification from the German Health Authority (Berlin). The ...
Indoco Remedies completes business transfer to Sunways India
Indoco Remedies has successfully completed the transfer of its ophthalmic business division to Sunways (India) Private Limited. This strategic move, finalised on May 18, 2026, involves the sale and tr...
Indoco Remedies receives EU GMP certification from Malta Medicines Authority
Indoco Remedies Ltd. has successfully obtained EU GMP certification for its manufacturing facility located at Baddi, following an inspection by the Malta Medicines Authority. The inspection took place...
Pharma sector stocks today, May 8: Indoco Remedies falls 6%, Natco Pharma jumps 2.57%, Mankind Pharma up 2.43%
Indian pharmaceutical stocks showed mixed performance in early trading on May 8, 2026. The S&P BSE Healthcare index was up 0.26% at 46,515.42, while the broader market declined, with Nifty…
Indoco Remedies Transcript: Q4 25/26
Q4 saw a strong turnaround with 25.8% YoY standalone revenue growth, led by international formulations, while domestic sales were muted due to seasonality. Debt remains high but is being managed, and no major CapEx is planned. Receivables and forex losses impacted financials.
Indoco Remedies Quarterly report: Q4 2026
Indoco Remedies has published its Q4 2026 quarterly earnings report on May 7, 2026.
Pharma sector stocks today, April 28: Glenmark Pharma surge 1.80%, Strides Pharma down 2%, Indoco Remedies up 1.52%
Indian pharmaceutical stocks opened the session on April 28, 2026, with a mixed tone. The Nifty Pharma Index stood at 23,132.0, down 0.2% in early trade, while the broader S&P BSE Healthcare Index…
Pharma sector stocks surge today, April 15: Indoco Remedies up 5%, Orchid Pharma gains 4.04%, Dr. Reddy's falls 1.64%
Indian pharmaceutical sector stocks traded higher in early morning trade on Tuesday, April 15, 2026, with most counters advancing while Dr. Reddy's Laboratories remained an outlier on the downside. Am...
Indoco Remedies receives USFDA final approval for Brivaracetam Oral Solution 10 mg/mL
Indoco Remedies Ltd. has secured final approval from the US Food and Drug Administration (USFDA) for its Abbreviated New Drug...
Indoco Remedies Transcript: Q3 25/26
Q3 FY26 saw strong export and API growth, improved subsidiary performance, and higher gross margins. Europe and OTC businesses are set for robust growth, while one-time costs from regulatory issues impacted results. Debt reduction and margin improvement remain key priorities.
Indoco Remedies Quarterly report: Q3 2026
Indoco Remedies has published its Q3 2026 quarterly earnings report on February 3, 2026.
Indoco Remedies Q3 Results: Revenue rises 8.5% YoY to Rs 445.4 crore, net loss at Rs 29.8 crore
Indoco Remedies reported its Q3 financial results, showing steady growth in revenue and operating profitability on a year-on-year basis, while...
Indoco Remedies Transcript: Q2 25/26
Q2 FY26 saw strong revenue growth and margin recovery, driven by robust India and emerging market performance, new product launches, and operational improvements. USFDA remediation and subsidiary losses remain key risks, but management expects further growth, margin expansion, and limited CapEx ahead.
Indoco Remedies Quarterly report: Q2 2026
Indoco Remedies has published its Q2 2026 quarterly earnings report on November 6, 2025.
Indoco Remedies’ Patalganga API facility clears USFDA inspection with zero observations
Indoco Remedies Limited, a leading Indian pharmaceutical company, announced today that its Active Pharmaceutical Ingredients (API) manufacturing facility at Patalganga, Navi Mumbai, has successfully p...
Why are Indoco Remedies shares up 2% today? Explained
Indoco Remedies Ltd shares climbed over 2% to ₹299.30 in morning trade on Tuesday after the company announced it has received final approval from the US Food and Drug Administration (USFDA) for its Ab...
Indoco Remedies gets USFDA nod for generic Rivaroxaban tablets; eyes growth in US Market
Mumbai-based Indoco Remedies Ltd. has secured final approval from the US Food and Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) to market Rivaroxaban Tablets USP in stren...
Indoco Remedies signs Sale and Leaseback Agreemen for Waluj facility assets
Indoco Remedies Limited has announced a strategic move involving the sale and leaseback of some of its movable assets at its Waluj Facility in Aurangabad, Maharashtra. In a regulatory filing, the comp...
Indoco Remedies Transcript: Q1 25/26
Q1 FY26 saw sequential revenue and EBITDA improvement, driven by OTC and emerging markets, despite ongoing FDA remediation and flat domestic formulations. Debt reduction and cost control efforts continue, with all plants expected fully operational by Q3.
Indoco Remedies Quarterly report: Q1 2026
Indoco Remedies has published its Q1 2026 quarterly earnings report on July 24, 2025.
Indoco Remedies Q1 Results: Revenue flat at Rs 42 crore, Net loss of Rs 3.6 crore
Indoco Remedies Limited reported a net loss of Rs 3.64 crore for the quarter ended June 30, 2025 (Q1FY26), compared to a profit of Rs 1.82 crore in the corresponding quarter last year. This marks the ...
Indoco Remedies receives EU GMP certification for sterile drug facility in Goa
Indoco Remedies Ltd has received a Certificate of EU Good Manufacturing Practices (GMP) Compliance from the European Health Authorities for its sterile drug product manufacturing facility at Goa Plant...
Indoco Remedies launches Ticagrelor tablets in UK through subsidiary
Indoco Remedies Limited has officially launched its Ticagrelor film-coated tablets (90mg) in the United Kingdom through its subsidiary, Indoco Remedies UK Limited, on June 2, 2025. This marks a signif...
Indoco Remedies receives USFDA approval for Generic Allopurinol Tablets USP 200 mg
Indoco Remedies Limited has received final approval from the United States Food and Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) for Allopurinol Tablets USP 200 mg. The ...